bioAffinity Technologies (BIAF) Income from Continuing Operations (2021 - 2026)

bioAffinity Technologies has disclosed Income from Continuing Operations across 6 years of filings, most recently posting 3630610.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 36.47% year-over-year to 3630610.0; the TTM figure through Mar 2026 stood at 15879947.0 (down 63.06% YoY), while the FY2025 annual figure was 14909754.0, down 64.93% from the prior year.
• Income from Continuing Operations fell to 3630610.0 in Q1 2026, from 3137466.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for BIAF reached as high as 88052.0 in Q2 2022 and fell as low as 5051084.0 in Q3 2025.
• The 5-year median for Income from Continuing Operations is 2290884.0 (2023), against an average of 2568901.12.
• Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 69.97% — and 2023, when it plunged 1876.3%.
• A 5-year view of Income from Continuing Operations shows it stood at 1674583.0 in 2022, then plunged by 41.72% to 2373164.0 in 2023, then fell by 25.02% to 2966897.0 in 2024, then fell by 5.75% to 3137466.0 in 2025, then decreased by 15.72% to 3630610.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 3630610.0, 3137466.0, and 5051084.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.